Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Zeuss LLC dba Zeuss

Has Zeuss received an FDA warning letter? Yes. FDA issued a warning letter dated February 20, 2026 concerning products containing tirzepatide.

Letter facts

Letter date
February 20, 2026 (2026-02-20)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Telehealth
Products named
compounded drug productscompounded tirzepatide drug products
Violation categories
MisbrandingFalse or misleading claims

Understanding these violation categories

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

False or misleading claims

FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.

Factual Violation Summary

FDA says the website falsely suggests Zeuss compounds the tirzepatide products and claims they are FDA-approved and clinically proven, rendering the compounded tirzepatide misbranded under FDCA 502(a) and 502(bb); products shipped interstate in violation of 301(a).

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • misbranding under FDCA 502(a)
  • misbranding under FDCA 502(bb)
  • false or misleading labeling and promotion
  • implied FDA approval of unapproved compounded drugs
  • misrepresentation of manufacturer/compounder identity
  • prohibited introduction into interstate commerce under FDCA 301(a)

More letters about Tirzepatide

Recent FDA warning letters concerning Tirzepatide:

Similar violations (Misbranding)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.